Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R7JT
|
|||
| Former ID |
DAP001105
|
|||
| Drug Name |
Fludrocortisone
|
|||
| Synonyms |
fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF; Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cerebral salt-wasting syndrome [ICD-11: 5C72; ICD-10: E87.1] | Approved | [1], [2] | |
| Therapeutic Class |
Antiinflammatory Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H29FO5
|
|||
| Canonical SMILES |
CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C(=O)CO)O)C)O)F
|
|||
| InChI |
1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
|
|||
| InChIKey |
AAXVEMMRQDVLJB-BULBTXNYSA-N
|
|||
| CAS Number |
CAS 127-31-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9217, 76336, 7891224, 7979235, 8172141, 10321611, 15375738, 24702328, 34673521, 46508616, 46508716, 48416020, 50019673, 50125791, 50864760, 56352851, 57311202, 71831474, 85286070, 96024662, 104234355, 104310733, 117567350, 123059725, 126651363, 126687973, 127307282, 127379594, 134338350, 135269929, 135650268, 137003338, 139326855, 144080988, 144206253, 144206895, 160963328, 160964032, 162176728, 164841599, 170464959, 175266519, 179214416, 196108113, 196404089, 223657072, 226396521, 249910373
|
|||
| ChEBI ID |
CHEBI:50885
|
|||
| ADReCS Drug ID | BADD_D00917 | |||
| SuperDrug ATC ID |
H02AA02
|
|||
| SuperDrug CAS ID |
cas=000127311
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Metabolic Reaction | Ester hydrolysis and reduction | |||
| Experimental Method | High-throughput screening | |||
| Description | Fludrocortisone acetate can be metabolized by gut microbiota through ester hydrolysis and reduction. | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2873). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010060. | |||
| REF 3 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
| REF 4 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||
| REF 5 | Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5. | |||
| REF 6 | Addison's disease. BMJ. 2009 Jul 2;339:b2385. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.